Azenta, Inc. CEO Resigns; Interim CEO Dr. Martin Madaus Named

What Happened

• Azenta, Inc. (AZTA) filed an 8-K on August 24, 2026 reporting that John P. Marotta resigned as President and Chief Executive Officer and as a director, effective August 22, 2026. The company said the resignation was not due to any disagreement with the company on operations, policies or practices.
• The Board reduced its size from nine to eight members and appointed Dr. Martin D. Madaus as Interim President and Chief Executive Officer effective August 22, 2026. Dr. Madaus also assumed the duties of Azenta’s principal executive officer for SEC reporting purposes.

Key Details

• Resignation effective date: August 22, 2026. 8-K filed: August 24, 2026.
• Board size reduced from nine to eight following the resignation.
• Interim CEO: Dr. Martin D. Madaus (age 66), Azenta director since January 2024 and Chair of the Nominating & Governance Committee (he will step down from that committee while serving as interim CEO).
• Background highlights for Dr. Madaus: Senior Operating Executive at Carlyle Group; former Chairman/President/CEO of Millipore (led sale to Merck KGaA for $7.2 billion) and roles leading Ortho Clinical Diagnostics and Roche Diagnostics; serves on boards of Repligen and Haemonetics.
• Company is reviewing additional compensation for Dr. Madaus in connection with his interim executive duties.
• A press release announcing the change was furnished as Exhibit 99.1 to the 8-K.

Why It Matters

• Executive leadership changes are material for investors because the CEO is responsible for company strategy, operations and SEC reporting. Azenta has named an experienced life‑science industry executive as interim CEO, which provides an immediately identifiable leader during the transition.
• The Board reduction and the company’s review of interim CEO compensation are concrete, near-term governance and cost items investors should note. The filing also states the resignation was not due to any disagreement, which addresses a common governance concern.